USD 2.17
(-0.46%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 77.61 Million USD | -19.31% |
2022 | 96.19 Million USD | -39.91% |
2021 | 160.08 Million USD | -25.77% |
2020 | 215.65 Million USD | 92.74% |
2019 | 111.89 Million USD | 15.06% |
2018 | 97.24 Million USD | 61.44% |
2017 | 60.23 Million USD | 95.22% |
2016 | 30.85 Million USD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 67.92 Million USD | -5.53% |
2024 Q1 | 71.9 Million USD | -7.36% |
2023 Q4 | 77.61 Million USD | -3.71% |
2023 Q1 | 100.64 Million USD | 4.63% |
2023 Q2 | 90.08 Million USD | -10.5% |
2023 FY | 77.61 Million USD | -19.31% |
2023 Q3 | 80.6 Million USD | -10.52% |
2022 Q3 | 112.62 Million USD | -16.66% |
2022 Q1 | 180.55 Million USD | 12.79% |
2022 Q2 | 135.13 Million USD | -25.15% |
2022 Q4 | 96.19 Million USD | -14.59% |
2022 FY | 96.19 Million USD | -39.91% |
2021 Q3 | 170.81 Million USD | -1.81% |
2021 Q4 | 160.08 Million USD | -6.28% |
2021 Q2 | 173.95 Million USD | -8.94% |
2021 Q1 | 191.03 Million USD | -11.42% |
2021 FY | 160.08 Million USD | -25.77% |
2020 FY | 215.65 Million USD | 92.74% |
2020 Q1 | 104.78 Million USD | -6.35% |
2020 Q2 | 208.83 Million USD | 99.3% |
2020 Q4 | 215.65 Million USD | 6.96% |
2020 Q3 | 201.61 Million USD | -3.46% |
2019 Q2 | 84.17 Million USD | -11.71% |
2019 Q3 | 120.73 Million USD | 43.44% |
2019 Q4 | 111.89 Million USD | -7.33% |
2019 FY | 111.89 Million USD | 15.06% |
2019 Q1 | 95.34 Million USD | -1.96% |
2018 Q2 | 39.29 Million USD | 0.0% |
2018 FY | 97.24 Million USD | 61.44% |
2018 Q4 | 97.24 Million USD | 93.9% |
2018 Q3 | 50.15 Million USD | 27.63% |
2018 Q1 | - USD | -100.0% |
2017 Q1 | - USD | 0.0% |
2017 Q4 | 60.23 Million USD | 0.0% |
2017 FY | 60.23 Million USD | 95.22% |
2016 FY | 30.85 Million USD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Abbott Laboratories | 73.21 Billion USD | 99.894% |
Allurion Technologies Inc. | 71.71 Million USD | -8.234% |
Artivion, Inc. | 792.39 Million USD | 90.205% |
Avanos Medical, Inc. | 1.69 Billion USD | 95.414% |
Butterfly Network, Inc. | 304.27 Million USD | 74.491% |
Butterfly Network, Inc. | 304.27 Million USD | 74.491% |
Bio-Rad Laboratories, Inc. | 12.29 Billion USD | 99.369% |
Boston Scientific Corporation | 35.13 Billion USD | 99.779% |
CONMED Corporation | 2.3 Billion USD | 96.625% |
Edwards Lifesciences Corporation | 9.36 Billion USD | 99.171% |
Paragon 28, Inc. | 340.69 Million USD | 77.218% |
Glaukos Corporation | 940.41 Million USD | 91.747% |
Globus Medical, Inc. | 5.08 Billion USD | 98.474% |
Inspire Medical Systems, Inc. | 676.81 Million USD | 88.532% |
Integer Holdings Corporation | 2.94 Billion USD | 97.362% |
Medtronic plc | 89.98 Billion USD | 99.914% |
Myomo, Inc. | 14.58 Million USD | -432.295% |
Nevro Corp. | 635.71 Million USD | 87.791% |
Owlet, Inc. | 44.12 Million USD | -75.911% |
Penumbra, Inc. | 1.55 Billion USD | 95.013% |
Vicarious Surgical Inc. | 119.86 Million USD | 35.246% |
Smith & Nephew plc | 9.98 Billion USD | 99.223% |
Sonendo, Inc. | 78.16 Million USD | 0.695% |
STERIS plc | 11.06 Billion USD | 99.298% |
Stryker Corporation | 39.91 Billion USD | 99.806% |
Zimmer Biomet Holdings, Inc. | 21.49 Billion USD | 99.639% |